Sonic Healthcare has delivered a mixed share price story over recent years, which puts fresh focus on whether the current valuation lines up with the cash it can generate. After a period of weaker long term returns followed by a shorter term rebound, the key issue for investors is how well the present share price reflects the company’s cash flow profile.
The issue now is whether Sonic Healthcare’s current share price is adequately supported by the cash flows implied by its intrinsic value estimates.
If you want to test the same cash flow lens you are using on Sonic Healthcare across a broader set of ideas, take a look at 2 high quality undervalued stocks.
The Discounted Cash Flow (DCF) model here looks at the cash Sonic Healthcare can return to shareholders over time and discounts it back to today. On this view, the group is generating meaningful cash already, with latest twelve month free cash flow of about A$750 million. Analyst projections in the model assume free cash flow holds at a solid level over the coming decade, then moderates, which points to a business seen as relatively mature rather than one priced purely on aggressive expansion.
The DCF output suggests Sonic Healthcare’s estimated intrinsic value sits meaningfully above the current A$21.33 share price. Because FY2026 results featured higher revenue, earnings and a lift in return on invested capital following LADR integration, the stronger operating picture helps explain why the cash flow based value indicator is more generous than the market price. That gap between the Discounted Cash Flow estimate and today’s quotation is what the detailed model is designed to quantify in A$ terms. Find out what Sonic Healthcare could be worth using our Discounted Cash Flow (DCF) estimate.
Sonic Healthcare Narratives on Simply Wall St sit between the cash flow model and the share price, spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth much more or less than it trades for today on the market. Rather than a single output from a ratio or valuation model, these frameworks describe the future that figure relies on, so you can watch over time whether that story holds up.
Bulls and bears are looking at the same Sonic Healthcare cash flows and drawing very different conclusions about what today’s price already reflects.
Bull case: 29% undervalued
According to Choppy, a Simply Wall St Community investor who wrote the Narrative, Sonic Healthcare’s edge is about footprint and technology.
"By moving into specialized testing, Sonic reduces its reliance on commodity testing and positions itself in the high-growth segment of molecular diagnostics…"
Discover why this Narrative puts Sonic Healthcare at 29% undervalued.
Bear case: 11% overvalued
The bearish analyst Narrative on Simply Wall St focuses on how execution and cost pressure could cap the upside from here.
"The combination of rising labour and funding costs, multi year profit decline and ongoing margin pressure in the U.S. suggests that even if volumes hold up…"
Explore why this Narrative puts Sonic Healthcare at 11% overvalued.
Cash flow models and market pricing only tell part of the story, because the people steering Sonic Healthcare and the way their pay is structured can heavily influence what happens from here. See who runs Sonic Healthcare and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com